Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 07, 2021 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10

Top-line results expected H1 2022Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindness LEIDEN, Netherlands...